Stay updated on Trastuzumab Deruxtecan in HER2 Mutant NSCLC Clinical Trial
Sign up to get notified when there's something new on the Trastuzumab Deruxtecan in HER2 Mutant NSCLC Clinical Trial page.

Latest updates to the Trastuzumab Deruxtecan in HER2 Mutant NSCLC Clinical Trial page
- Check3 days agoChange DetectedThe page history now lists Revision: v3.6.2, replacing v3.6.0. This reflects a small update to the page’s versioning rather than a change to the study data or visible content.SummaryDifference0.1%

- Check10 days agoNo Change Detected
- Check17 days agoChange DetectedThe study record now indicates that no more participants are being recruited. The record has been updated to version v3.6.0, replacing the prior revision.SummaryDifference0.3%

- Check24 days agoChange DetectedThe version history now displays a new revision entry (v3.5.5) and removes the preceding revision (v3.5.4), reflecting an updated record meta.SummaryDifference0.1%

- Check46 days agoChange DetectedRecord History now includes added sections for Adverse Events, Outcome Measures, Participant Flow, and References. A new version entry dated 2026-05-12 indicates updated content in the study record.SummaryDifference0.8%

- Check67 days agoChange DetectedThe page’s revision/version indicator was updated from **v3.5.2** to **v3.5.3**, reflecting a site or interface release rather than substantive trial-record changes.SummaryDifference0.1%

- Check75 days agoChange DetectedAdded revision v3.5.2 and removed revision v3.5.0 from the study record history.SummaryDifference0.1%

Stay in the know with updates to Trastuzumab Deruxtecan in HER2 Mutant NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Trastuzumab Deruxtecan in HER2 Mutant NSCLC Clinical Trial page.